|
1
|
Iwakiri K, Kinoshita Y, Habu Y, Oshima T,
Manabe N, Fujiwara Y, Nagahara A, Kawamura O, Iwakiri R, Ozawa S,
et al: Evidence-based clinical practice guidelines for
gastroesophageal reflux disease 2015. J Gastroenterol. 51:751–767.
2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
El-Serag H, Becher A and Jones R:
Systematic review: Persistent reflux symptoms on proton pump
inhibitor therapy in primary care and community studies. Aliment
Pharmacol Ther. 32:720–737. 2010.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Frazzoni M, Conigliaro R and Melotti G:
Weakly acidic refluxes have a major role in the pathogenesis of
proton pump inhibitor-resistant reflux oesophagitis. Aliment
Pharmacol Ther. 33:601–606. 2011.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Iwakiri K, Sano H, Tanaka Y, Kawami N,
Umezawa M, Futagami S, Hoshihara Y, Nomura T, Miyashita M and
Sakamoto C: Characteristics of symptomatic reflux episodes in
patients with non-erosive reflux disease who have a positive
symptom index on proton pump inhibitor therapy. Digestion.
82:156–161. 2010.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Kagami T, Sahara S, Ichikawa H, Uotani T,
Yamade M, Sugimoto M, Hamaya Y, Iwaizumi M, Osawa S, Sugimoto K, et
al: Potent acid inhibition by vonoprazan in comparison with
esomeprazole, with reference to CYP2C19 genotype. Aliment Pharmacol
Ther. 43:1048–1059. 2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Mori H and Suzuki H: Role of acid
suppression in acid-related diseases: proton pump inhibitor and
potassium-competitive acid blocker. J Neurogastroenterol Motil.
25:6–14. 2019.PubMed/NCBI View
Article : Google Scholar
|
|
7
|
Shinozaki S, Kobayashi Y, Osawa H,
Sakamoto H, Hayashi Y, Lefor AK and Yamamoto H: Effectiveness and
safety of vonoprazan versus proton pump inhibitors for second-line
Helicobacter pylori eradication therapy: systematic review
and meta-analysis. Digestion. 1–7. 2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Shinozaki S, Osawa H, Hayashi Y, Sakamoto
H, Kobayashi Y, Lefor AK and Yamamoto H: Vonoprazan 10 mg daily is
effective for the treatment of patients with proton pump
inhibitor-resistant gastroesophageal reflux disease. Biomed Rep.
7:231–235. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Iwakiri K, Sakurai Y, Shiino M, Okamoto H,
Kudou K, Nishimura A, Hiramatsu N, Umegaki E and Ashida K: A
randomized, double-blind study to evaluate the acid-inhibitory
effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump
inhibitor-resistant erosive esophagitis. Therap Adv Gastroenterol.
10:439–451. 2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Yamashita H, Kanamori A, Kano C, Hashimura
H, Matsumoto K, Tsujimae M, Yoshizaki T, Momose K, Obata D, Eguchi
T, et al: The Effects of switching to vonoprazan, a novel
potassium-competitive acid blocker, on gastric acidity and reflux
patterns in patients with erosive esophagitis refractory to proton
pump inhibitors. Digestion. 96:52–59. 2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Okuyama M, Nakahara K, Iwakura N, Hasegawa
T, Oyama M, Inoue A, Ishizu H, Satoh H and Fujiwara Y: Factors
associated with potassium-competitive acid blocker non-response in
patients with proton pump inhibitor-refractory gastroesophageal
reflux disease. Digestion. 95:281–287. 2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Hoshino S, Kawami N, Takenouchi N, Umezawa
M, Hanada Y, Hoshikawa Y, Kawagoe T, Sano H, Hoshihara Y, Nomura T,
et al: Efficacy of vonoprazan for proton pump inhibitor-resistant
reflux esophagitis. Digestion. 95:156–161. 2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Kakuta E, Yamashita N, Katsube T,
Kushiyama Y, Suetsugu H, Furuta K and Kinoshita Y: Abdominal
symptom-related QOL in individuals visiting an outpatient clinic
and those attending an annual health check. Intern Med.
50:1517–1522. 2011.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Shinozaki S, Osawa H, Kobayashi Y,
Sakamoto H, Hayashi Y, Miura Y, Kawarai Lefor A and Yamamoto H:
Long-term outcomes of patients with symptomatic gastroesophageal
reflux disease treated with vonoprazan. Scand J Gastroenterol.
53:897–904. 2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Lundell LR, Dent J, Bennett JR, Blum AL,
Armstrong D, Galmiche JP, Johnson F, Hongo M, Richter JE, Spechler
SJ, et al: Endoscopic assessment of oesophagitis: Clinical and
functional correlates and further validation of the Los Angeles
classification. Gut. 45:172–180. 1999.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Kimura K and Takemoto T: An endoscopic
recognition of the atrophic border and its significance in chronic
gastritis. Endoscopy. 1:87–97. 1969.
|
|
17
|
Furuta K, Ishihara S, Sato S, Miyake T,
Ishimura N, Koshino K, Tobita H, Moriyama I, Amano Y, Adachi K, et
al: Development and verification of the Izumo Scale, new
questionnaire for quality of life assessment of patients with
gastrointestinal symptoms. Nihon Shokakibyo Gakkai Zasshi.
106:1478–1487. 2009.PubMed/NCBI(In Japanese).
|
|
18
|
Fujishiro M, Kushiyama A, Yamazaki H,
Kaneko S, Koketsu Y, Yamamotoya T, Kikuchi T, Sakoda H, Suzuki R
and Kadowaki T: Gastrointestinal symptom prevalence depends on
disease duration and gastrointestinal region in type 2 diabetes
mellitus. World J Gastroenterol. 23:6694–6704. 2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Kinoshita Y and Chiba T: FUTURE Study
Group. Characteristics of Japanese patients with chronic gastritis
and comparison with functional dyspepsia defined by ROME III
criteria: Based on the large-scale survey, FUTURE study. Intern
Med. 50:2269–2276. 2011.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Okimoto E, Ishimura N, Morito Y, Mikami H,
Shimura S, Uno G, Tamagawa Y, Aimi M, Oshima N, Kawashima K, et al:
Prevalence of gastroesophageal reflux disease in children, adults,
and elderly in the same community. J Gastroenterol Hepatol.
30:1140–1146. 2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Shinozaki S, Osawa H, Sakamoto H, Hayashi
Y, Kawarai Lefor A and Yamamoto H: The effect of acotiamide on
epigastric pain syndrome and postprandial distress syndrome in
patients with functional dyspepsia. J Med Invest. 63:230–235.
2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Tanabe T, Hoshino S, Kawami N, Hoshikawa
Y, Hanada Y, Takenouchi N, Goto O, Kaise M and Iwakiri K: Efficacy
of long-term maintenance therapy with 10-mg vonoprazan for proton
pump inhibitor-resistant reflux esophagitis. Esophagus. 16:377–381.
2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Fass R and Sifrim D: Management of
heartburn not responding to proton pump inhibitors. Gut.
58:295–309. 2009.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Hershcovici T, Jha LK, Cui H, Powers J and
Fass R: Night-time intra-oesophageal bile and acid: A comparison
between gastro-oesophageal reflux disease patients who failed and
those who were treated successfully with a proton pump inhibitor.
Aliment Pharmacol Ther. 33:837–844. 2011.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Masaoka T, Kameyama H, Yamane T, Yamamoto
Y, Takeuchi H, Suzuki H, Kitagawa Y and Kanai T: Pathophysiology of
potassium-competitive acid blocker-refractory gastroesophageal
reflux and the potential of potassium-competitive acid blocker
test. J Neurogastroenterol Motil. 24:577–583. 2018.PubMed/NCBI View
Article : Google Scholar
|
|
26
|
Pinto-Sanchez MI, Yuan Y, Hassan A, Bercik
P and Moayyedi P: Proton pump inhibitors for functional dyspepsia.
Cochrane Database Syst Rev. 11(CD011194)2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Miwa H, Nakajima K, Yamaguchi K, Fujimoto
K, Veldhuyzen VAN, Zanten SJ, Kinoshita Y, Adachi K, Kusunoki H and
Haruma K: Generation of dyspeptic symptoms by direct acid infusion
into the stomach of healthy Japanese subjects. Aliment Pharmacol
Ther. 26:257–264. 2007.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Ishii M, Manabe N, Kusunoki H, Kamada T,
Sato M, Imamura H, Shiotani A, Hata J and Haruma K: Real-time
evaluation of dyspeptic symptoms and gastric motility induced by
duodenal acidification using noninvasive transnasal endoscopy. J
Gastroenterol. 43:935–941. 2008.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Ichikawa H, Sugimoto M, Sugimoto K, Andoh
A and Furuta T: Rapid metabolizer genotype of CYP2C19 is a risk
factor of being refractory to proton pump inhibitor therapy for
reflux esophagitis. J Gastroenterol Hepatol. 31:716–726.
2016.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Takeuchi T, Furuta T, Fujiwara Y, Sugimoto
M, Kasugai K, Kusano M, Okada H, Suzuki T, Higuchi T, Kagami T, et
al: Randomised trial of acid inhibition by vonoprazan 10/20 mg once
daily vs rabeprazole 10/20 mg twice daily in healthy Japanese
volunteers (SAMURAI pH study). Aliment Pharmacol Ther. 51:534–543.
2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Sakurai Y, Mori Y, Okamoto H, Nishimura A,
Komura E, Araki T and Shiramoto M: Acid-inhibitory effects of
vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10
mg in healthy adult male subjects - a randomised open-label
cross-over study. Aliment Pharmacol Ther. 42:719–730.
2015.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Kinoshita Y, Sakurai Y, Takabayashi N,
Kudou K, Araki T, Miyagi T, Iwakiri K and Ashida K: Efficacy and
safety of vonoprazan in patients with nonerosive gastroesophageal
reflux disease: a randomized, placebo-controlled, phase 3 study.
Clin Transl Gastroenterol. 10(e00101)2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Sugimoto M, Ban H, Hira D, Kamiya T,
Otsuka T, Inatomi O, Bamba S, Terada T and Andoh A: Letter:
CYP3A4/5 genotype status and outcome of vonoprazan-containing
Helicobacter pylori eradication therapy in Japan. Aliment
Pharmacol Ther. 45:1009–1010. 2017.PubMed/NCBI View Article : Google Scholar
|
